<div id="readability-page-1"><div><p>Health-care companies rose amid deal activity.</p><p>    Biomarin Pharmaceutical agreed to buy fellow biotechnology company Amicus Therapeutics for about $4.8 billion. Amicus founder and longtime leader, John Crowley started the company to find a cure for his two children's rare disease. </p><p>    Nine pharmaceutical companies, including Merck and British drug giant GSK, agreed to lower certain U.S. prices for their medicines in a new round of industry pacts with the Trump administration. </p><p>   Write to Rob Curran at rob.curran@dowjones.com </p><p>    (END) Dow Jones Newswires</p><p>12-19-25 1732ET</p></div></div>

葛蘭素史克

愛美醫療

<p>醫療保健公司在交易活動中上漲。Biomarin Pharmaceutical 同意以約 48 億美元收購生物技術公司 Amicus Therapeutics。Amicus 的創始人和長期領導者 John Crowley 創辦該公司是為了尋找治癒他兩個孩子罕見疾病的方法。包括默克和英國製藥巨頭 GSK 在內的九家制藥公司同意在與特朗普政府的新一輪行業協議中降低其某些藥品在美國的價格。請聯繫 Rob Curran，郵箱為 rob.curran@dowjones.com (完) 道瓊斯新聞社 12-19-25 1732ET</p>

由於交易活動的增加，醫療保健行業上漲——醫療保健綜述